S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Asian shares mixed after last week's gains on Wall Street
NASDAQ:DCPH

Deciphera Pharmaceuticals - DCPH Stock Forecast, Price & News

$17.31
-0.67 (-3.73%)
(As of 01/27/2023 08:54 PM ET)
Add
Compare
Today's Range
$17.22
$18.08
50-Day Range
$14.85
$22.10
52-Week Range
$6.51
$22.76
Volume
477,100 shs
Average Volume
1.18 million shs
Market Capitalization
$1.17 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$22.00

Deciphera Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.56 Rating Score
Upside/​Downside
27.1% Upside
$22.00 Price Target
Short Interest
Healthy
9.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.55
Upright™ Environmental Score
News Sentiment
0.78mentions of Deciphera Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
$30 M Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.49) to ($2.32) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.78 out of 5 stars

Medical Sector

40th out of 1,049 stocks

Pharmaceutical Preparations Industry

15th out of 514 stocks


DCPH stock logo

About Deciphera Pharmaceuticals (NASDAQ:DCPH) Stock

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Stock News Headlines

Deciphera Pharmaceuticals (NASDAQ:DCPH) PT Raised to $30.00
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Deciphera Pharma Prices Public Offering Of 6.94 Mln Shares At $18/shr
Why Deciphera Pharmaceuticals Stock Is Nosediving
Where Deciphera Pharmaceuticals Stands With Analysts
DCPH Deciphera Pharmaceuticals, Inc.
See More Headlines
Receive DCPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Deciphera Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

DCPH Company Calendar

Last Earnings
11/03/2022
Today
1/30/2023
Next Earnings (Estimated)
2/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DCPH
Fax
N/A
Employees
280
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$22.00
High Stock Price Forecast
$30.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+27.1%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Net Income
$-299,960,000.00
Net Margins
-177.53%
Pretax Margin
-181.63%

Debt

Sales & Book Value

Annual Sales
$96.15 million
Book Value
$5.21 per share

Miscellaneous

Free Float
64,729,000
Market Cap
$1.17 billion
Optionable
Optionable
Beta
0.73

Key Executives

  • Mr. Steven L. Hoerter (Age 52)
    Pres, CEO & Director
    Comp: $1.01M
  • Dr. Daniel L. Flynn Ph.D. (Age 68)
    Exec. VP, Chief Scientific Officer & Founder
    Comp: $645.61k
  • Mr. Thomas Patrick Kelly J.D.Mr. Thomas Patrick Kelly J.D. (Age 52)
    Exec. VP, CFO & Treasurer
    Comp: $644.12k
  • Mr. Daniel C. Martin (Age 48)
    Sr. VP & Chief Commercial Officer
    Comp: $611.24k
  • Dr. Matthew L. Sherman M.D.Dr. Matthew L. Sherman M.D. (Age 67)
    Exec. VP & Chief Medical Officer
    Comp: $725.85k
  • Dr. Stephen B. Ruddy Ph.D. (Age 59)
    Sr. VP & Chief Technical Officer
  • Jennifer Larson
    Sr. VP of Fin. & Investor Relations
  • Mr. Jeffrey M. Held J.D.
    Sr. VP & Gen. Counsel
  • Ms. Lisa Amaya Price
    Sr. VP & Chief HR Officer
  • Ms. Jama Pitman (Age 44)
    Sr. VP of Regulatory, Quality & Portfolio Management













DCPH Stock - Frequently Asked Questions

Should I buy or sell Deciphera Pharmaceuticals stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last year. There are currently 1 sell rating, 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" DCPH shares.
View DCPH analyst ratings
or view top-rated stocks.

What is Deciphera Pharmaceuticals' stock price forecast for 2023?

9 brokerages have issued 1 year target prices for Deciphera Pharmaceuticals' shares. Their DCPH share price forecasts range from $9.00 to $30.00. On average, they predict the company's stock price to reach $22.00 in the next year. This suggests a possible upside of 27.1% from the stock's current price.
View analysts price targets for DCPH
or view top-rated stocks among Wall Street analysts.

How have DCPH shares performed in 2023?

Deciphera Pharmaceuticals' stock was trading at $16.39 at the beginning of the year. Since then, DCPH stock has increased by 5.6% and is now trading at $17.31.
View the best growth stocks for 2023 here
.

When is Deciphera Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our DCPH earnings forecast
.

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) issued its earnings results on Thursday, November, 3rd. The company reported ($0.55) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.02. The company had revenue of $35.97 million for the quarter, compared to the consensus estimate of $33.29 million. Deciphera Pharmaceuticals had a negative net margin of 177.53% and a negative trailing twelve-month return on equity of 63.88%.

What guidance has Deciphera Pharmaceuticals issued on next quarter's earnings?

Deciphera Pharmaceuticals issued an update on its fourth quarter 2022 earnings guidance on Tuesday, January, 3rd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $36.00 million-$36.00 million, compared to the consensus revenue estimate of $34.83 million.

What is Steve Hoerter's approval rating as Deciphera Pharmaceuticals' CEO?

3 employees have rated Deciphera Pharmaceuticals Chief Executive Officer Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among the company's employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Deciphera Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Who are Deciphera Pharmaceuticals' major shareholders?

Deciphera Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Assenagon Asset Management S.A. (1.50%), Allspring Global Investments Holdings LLC (0.14%), Hennion & Walsh Asset Management Inc. (0.10%) and Inspire Investing LLC (0.02%). Insiders that own company stock include Brightstar Associates Llc, Daniel Lee Flynn, Jama Pitman, James Arthur Bristol, Matthew L Sherman, Michael Douglas Taylor, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends
.

How do I buy shares of Deciphera Pharmaceuticals?

Shares of DCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Deciphera Pharmaceuticals' stock price today?

One share of DCPH stock can currently be purchased for approximately $17.31.

How much money does Deciphera Pharmaceuticals make?

Deciphera Pharmaceuticals (NASDAQ:DCPH) has a market capitalization of $1.17 billion and generates $96.15 million in revenue each year. The company earns $-299,960,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis.

How many employees does Deciphera Pharmaceuticals have?

The company employs 280 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The official website for the company is www.deciphera.com. The company can be reached via phone at (781) 209-6400 or via email at eciphera@argotpartners.com.

This page (NASDAQ:DCPH) was last updated on 1/30/2023 by MarketBeat.com Staff